Dr Dawn Driscoll appointed as CEO at Cell Therapies Pty Ltd

October 4th, 2017 | Posted by webmaster in News - (Comments Off on Dr Dawn Driscoll appointed as CEO at Cell Therapies Pty Ltd)

Cell Therapies Pty Ltd is delighted to announce the appointment of Dr Dawn Driscoll as its new Chief Executive Officer.

Dawn is highly experienced in the cellular therapy industry and has over 20 years experience in the biotechnology industry globally, with expertise in cell therapy, licensing, acquisitions and commercialisation.

The Board of Cell Therapies and Peter Mac as the majority shareholder is very pleased to have Dawn join and lead our team.

Our company is in good shape and in a great position to lead the Asia-Pacific market in this exciting time as new CAR-T cell therapies and other immunotherapies come to market. Our unique offering in lab-to-benchside cellular vaccine development, manufacture and clinical treatment within a hospital and academic research institute sets us apart from our competitors. We have a track record of novel and first-in human trials rapidly delivered to the highest grade GMP.

The Board would also like to thank Dr Dominic Wall for his leadership during this transition period.

A/Prof Leslie Reti
Chairman of Cell Therapies Pty Ltd Board of Directors

CTPL awarded Australian Global Innovation Linkages programme grant

June 26th, 2017 | Posted by webmaster in News - (Comments Off on CTPL awarded Australian Global Innovation Linkages programme grant)

Melbourne, Australia 26 June 2017: Cell Therapies has been awarded $1,000,000 in funding by the Australian Government Department of Industry, Innovation and Science through the Global Innovation Linkages programme.  On 10 April 2017, CTPL was announced as one of the nine successful Australian businesses and research organisations to be granted Round 1 funding to collaborate with global partners in science, research and development projects.

Cell Therapies was the lead applicant for the grant, forging a collaboration with 5 other organisations from Australia and the United States, to translate the development of an innovative dual-imaging cell tracking agent into cancer immunotherapy clinical studies as the next step towards commercialisation.

About Global Innovation Linkages Programme 

The Global Innovation Linkages programme provides funding to help Australian businesses and researchers to collaborate with global partners on strategically focused, leading-edge research and development projects.  More information about the Global Innovation Linkages programme is available at https://www.business.gov.au/assistance/global-innovation-linkages-programme.

About Cell Therapies Pty Ltd

Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for Asian deployment of cellular therapies for our clients.

CTPL receives APAC Bioprocessing Excellence Award

February 20th, 2017 | Posted by webmaster in News - (Comments Off on CTPL receives APAC Bioprocessing Excellence Award)

Melbourne, Australia 20 February 2017: Cell Therapies commitment to, and excellence in, bringing innovative cellular therapies into clinical practise has been recognised with an IMAPAC Asia-Pacific Bioprocessing Excellence Award. Managing Director and  CEO Dr Tim Oldham accepted the award for “Best Bioprocessing Excellence in Australia (CMO Category)” at an awards ceremony in Singapore on 15 February.

“It is an honour to receive this award on behalf of our talented and committed team” said Dr Oldham after the ceremony. “This award recognizes both the critical role that specialized manufacturing and supply chain capabilities will play in ensuring patient access to innovative cell and gene therapies that can transform health outcomes, and confirms Cell Therapies’ leadership in the field in Asia Pacific”.

About APAC Bioprocessing Excellence Awards 

APAC Bioprocessing Excellence Awards aim to recognize outstanding bioprocessing people, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and bets practices in manufacturing, Asia’s Bioprocessing Excellence Awards aim to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow.

About Cell Therapies Pty Ltd

Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia and PharmaBio Corp in Japan, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for Asian deployment of cellular therapies for our clients.

CTPL CEO, Tim Oldham, elected to Alliance for Regenerative Medicine 2017 Board of Directors

October 26th, 2016 | Posted by webmaster in News - (Comments Off on CTPL CEO, Tim Oldham, elected to Alliance for Regenerative Medicine 2017 Board of Directors)

Melbourne, Australia, 11 October 2016: Cell Therapies Pty Ltd (CTPL) is pleased to announce that CEO and Managing Director Dr Tim Oldham has been elected to the Board of the Alliance for Regenerative Medicine (ARM) for 2017.

AusBiotech CEO Glenn Cross said: “On behalf of the Regenerative Medicine Advisory Group (RMAG) and AusBiotech, I would like to congratulate Tim Oldham on being elected to the Alliance for Regenerative Medicine 2017 Board of Directors. This is a prestigious position in an important and promising area of Australian medicine. Dr Oldham is a valuable member of the RMAG, and we look forward to working with Dr Oldham on future projects.”

ARM is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide. By leveraging the expertise of its membership, ARM empowers multiple stakeholders to promote legislative, regulatory and public understanding of, and support for, this expanding field. Based in Washington, DC, ARM promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.

“ARM leadership reflects the geographical and technological diversity of our membership,” said Morrie Ruffin, managing director of ARM in ARM’s announcement of the 2017 leadership. “We welcome these new slates of officers, directors and executive committee members; each has demonstrated direct involvement and active participation in ARM’s activities and has made vital contributions to the advancement of this sector.”

“I look forward to continuing CTPL’s significant contribution to our industry through this appointment, and in particular to increasing the voice and profile of AusBiotech’s Regenerative Medicine Advisory Group and the Australian industry in general” said Dr Oldham.

http://alliancerm.org/press/alliance-regenerative-medicine-announces-election-2017-arm-officers%2C-executive-committee-and

 

ISCT 2016

August 19th, 2016 | Posted by webmaster in News | Uncategorized - (Comments Off on ISCT 2016)

CT’s contribution to ISCT 2016

Representatives from Cell Therapies presented at ISCT Singapore on the following topics:

Apheresis – Douglas Watson, Cell Therapy Specialist

Initial Comparison of 3 apheresis platforms for supporting the collection of CD3+ cells for CAR-T production

Flow Cytometry – Alex Rizzitelli, Cell Therapy Specialist

Flow cytometry tools for characterisation of GMP cell products

COGS Optimisation – Tim Oldham, CEO

COGS by Design – A systems approach to achieving commercially viable cellular therapy products

Australian Cell Therapy Landscape – Tim Oldham, CEO

Advantage Australia – A Stepping stone to Asian and global development of cellular therapies

Apheresis for cellular therapy manufacturing: need for improved collection data

February 8th, 2016 | Posted by webmaster in News - (Comments Off on Apheresis for cellular therapy manufacturing: need for improved collection data)

Melbourne 8 Feb 2016: Cell collection via apheresis is the starting point for manufacture of many cellular therapies, including most immuno-therapies. The high patient-to-patient variability, coupled with the specialised skills needed for these collections mean manufacturers have to deal with significant variation in incoming cellular material. Manufacturers are only now coming to grips with the implications of this variation, let alone how to manage and control it. Cell Therapies Pty Ltd CEO Tim Oldham discussed the importance of understanding apheresis variability and approaches to managing and controlling it at the recent Cell & Gene Therapy Leaders Forum in Washington DC (see the presentation Managing apheresis as source of cellular therapy starting material) and Alexey Bersenev has followed up with a useful blog at Stem Cell Assays (http://stemcellassays.com/2016/01/standardization-of-apheresis-collections-for-cell-product-manufacturing/#comments). Dr Oldham argued that collating collection data across many centres and collections to enable apheresis variability to be characterized and understood, and to benchmark individual site, operator and collection performance would be an invaluable tool to aid manufacturing process development.

Reform Needed To Fulfill Our Biotech Potential

October 7th, 2015 | Posted by webmaster in News - (Comments Off on Reform Needed To Fulfill Our Biotech Potential)

REFORM NEEDED TO FULFILL OUR BIOTECH POTENTIAL is an article by AusBiotech’s Chief Executive, Dr Anna Lavelle, published in Melbourne’s Herald Sun on the 25 September 2015.  Dr Lavelle’s article refers to a young and promising Australian biotech industry that “has potential to be our future”.  Cell Therapies is one of a number of examples used to illustrate this point.  However, Dr Lavelle says that “reforms are needed in tax and capital attraction, clinical trials approvals, reimbursement, regulation and how we fund commercialisation and translation of our technologies” if we are to achieve this potential.  See the full article by clicking onto the following link:  http://www.pressreader.com/australia/herald-sun/20150925/282467117695750/TextView or alternatively by clicking here Herald Sun 25 September 2015.

Confirmation of BioNexus Award to CTPL

October 5th, 2015 | Posted by webmaster in News - (Comments Off on Confirmation of BioNexus Award to CTPL)

Melbourne and Kuala Lumpur 30 Sep 2015: Cell Therapies Pty Ltd (CTPL) has today received official notification from the Malaysian Government and Malaysian Biotechnology Corporation (BiotechCorp) that its Malaysian subsidiary, Cell Therapies Malaysia Sdn Bhd (CTMSB) has been awarded BioNexus status having met the conditions of the letter of offer made in February. The BioNexus status confers a ten year tax exemption on CTMSB profits provided that CTMSB commences its qualifying activities by 6 July 2016, invests 3% of revenue in R&D annually and maintains 65% of its workforce as knowledge workers.

CTPL CEO Tim Oldham commented that: “We are looking forward to partnering with the Malaysian government to establish a world class manufacturing hub for cellular therapies in Malaysia and contribute to Malaysia’s bioeconomy. From our planned Malaysian facility we expect to be able to supply a wide range of high quality, evidence based cellular therapies on a commercial scale to ASEAN and beyond. This facility will receive operating and process know-how from our existing facility at our Founding Partner, Peter MacCallum Cancer Institute in Melbourne, and compliment its capacity.”

About Cell Therapies Pty Ltd:

Cell Therapies is the leading manufacturer and distributor of cellular therapies in Asia Pacific, a region of over 650 million people. Cell Therapies provides the essential manufacturing and distribution infrastructure for the safe, reliable and scalable delivery of cellular therapies into clinical trials and for therapeutic use.

For over a decade, Cell Therapies has made these capabilities available on a contract basis to some of the world’s leading stem cell companies, developing products and processes that are compliant with global regulatory and cGMP requirements and successfully integrating with global manufacturing networks. Cell Therapies also in-licenses late stage products for high unmet clinical need for commercialisation in SE Asia and Australasia.

CTPL CSO Dominic Wall comments on opportunities and challenges of CAR-T therapy in lead-up to AusBiotech 2015

September 25th, 2015 | Posted by webmaster in News - (Comments Off on CTPL CSO Dominic Wall comments on opportunities and challenges of CAR-T therapy in lead-up to AusBiotech 2015)

Cell Therapies’ Chief Scientific Officer, Dr Dominic Wall will participate in AusBiotech2015 as part of the Regenerative Medicine Forum. He is quoted today in an article by Sue Dunlevy highlighting the opportunities for improved cancer outcomes emerging from CAR-T research and the remaining challenges of manufacturing these patient specific therapies cost effectively. See the full article here: http://www.news.com.au/news/what-if-we-cant-afford-the-cure-for-cancer/story-fnihsrk2-1227542906466

CTPL featured in Australasian Biotechnology Advanced Manufacturing Feature

September 22nd, 2015 | Posted by webmaster in News - (Comments Off on CTPL featured in Australasian Biotechnology Advanced Manufacturing Feature)

Cell Therapies Pty Ltd has been profiled in Australian Biotechnology’s most recent edition featuring advanced manufacturing. As cellular therapies transform healthcare for many unmet medical needs, new manufacturing capacity with unique skills in just-in-time production systems integrated with clinical point of care will be critical. CTPL provides this enabling infrastructure and with our founding partner and major shareholder Peter Mac we sit at the intersection of translational research, clinical trials and standard of care delivery. Contributing to both Victoria’s Future Industries Medical Technologies and Pharmaceuticals Advanced Manufacturing Strategy (http://yoursay.business.vic.gov.au/futureindustries/medical-technologies-pharmaceuticals) and the Victorian Health and Medical Research Strategy (http://www.health.vic.gov.au/healthandmedicalresearch/strategy) we are proud to be part of an advanced manufacturing eco-system that can be both a local manufacturing hub and employer and a significant exporter. The full journal can be found here: http://www.ausbiojournals.org/digimag/Oct2015/digimag.html

To view the article please click here AusBiotech Advanced Manufacturing CTPL Profile